Edgewise Therapeutics raises $95M to fund muscular-dystrophy drug trials

BOULDER — Edgewise Therapeutics Inc. has more than doubled its previous fundraising rounds by closing a $95 million Series C round as it embarks on its first clinical trial for its muscular dystrophy drug candidate.

The Boulder company said Wednesday that the funds will primarily go toward clinical testing of its lead drug candidate EDG-5506, and also be used to pursue future licensing agreements and clinical research collaborations with other rare-disease drug developers.

The round is on top of the $50 million it raised in 2019 and brings its total venture-capital dollars to $160.5 million.